0001209191-23-042110.txt : 20230712 0001209191-23-042110.hdr.sgml : 20230712 20230712180620 ACCESSION NUMBER: 0001209191-23-042110 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230710 FILED AS OF DATE: 20230712 DATE AS OF CHANGE: 20230712 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Doerfler Douglas CENTRAL INDEX KEY: 0001874482 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40674 FILM NUMBER: 231085424 MAIL ADDRESS: STREET 1: C/O MAXCYTE, INC. STREET 2: 22 FIRSTFIELD ROAD, SUITE 110 CITY: GAITHERSBURG STATE: MD ZIP: 20878 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MAXCYTE, INC. CENTRAL INDEX KEY: 0001287098 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 522210438 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9713 KEY WEST AVENUE, STREET 2: SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-517-5556 MAIL ADDRESS: STREET 1: 9713 KEY WEST AVENUE, STREET 2: SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: MAXCYTE INC DATE OF NAME CHANGE: 20040415 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-07-10 0 0001287098 MAXCYTE, INC. MXCT 0001874482 Doerfler Douglas C/O MAXCYTE, INC. 9713 KEY WEST AVENUE, SUITE 400 ROCKVILLE MD 20850 1 1 0 0 President and CEO 1 Common Stock 2023-07-10 4 M 0 445 0.04 A 333642 D Common Stock 2023-07-10 4 S 0 445 5.01 D 333197 D Common Stock 2023-07-11 4 M 0 12798 0.04 A 345995 D Common Stock 2023-07-11 4 S 0 12798 5.04 D 333197 D Common Stock 2023-07-12 4 M 0 16757 0.04 A 349954 D Common Stock 2023-07-12 4 S 0 16757 5.02 D 333197 D Employee Stock Option (right to buy) 0.04 2023-07-10 4 M 0 445 0.00 D 2024-11-11 Common Stock 445 264635 D Employee Stock Option (right to buy) 0.04 2023-07-11 4 M 0 12798 0.00 D 2024-11-11 Common Stock 12798 251837 D Employee Stock Option (right to buy) 0.04 2023-07-12 4 M 0 16757 0.00 D 2024-11-11 Common Stock 16757 235080 D The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.005 to $5.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.085, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This option is fully vested and exercisable. /s/ Brian F. Leaf, Attorney-in-Fact 2023-07-12